As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present just as many opportunities as pitfalls. People taking the drugs do indeed eat less—especially indulgent treats.

Here's what to know about weight loss drugs such as Wegovy and Zepbound. CR helps you decide whether semaglutide or tirzepatide is right for you.

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims shared with Reuters.

The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from obesity procedures.

Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new tally finds. "In contrast, there was a 25.6% decrease in patients undergoing metabolic bariatric surgery" during the same time period,